Longitudinal BRAF ctDNA monitoring in melanoma reflects disease status and predicts relapse.

doi:10.1016/j.jdermsci.2026.07.004

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Longitudinal BRAF ctDNA monitoring in melanoma reflects disease status and predicts relapse.

Journal of dermatological science - 1 Sept 2026

Rizo-Potau Daniel, Forniés-Mariné Anton, Aguilar Michelle, Verdura Edgard, Montalbán-Casafont Aina, Serra-García Laura, Podlipnik Sebastian, Carrera Cristina, Puig Susana, Malvehy Josep, Puig-Butillé Joan Anton

Abstract excerpt

BACKGROUND: Early detection of melanoma relapse after curative-intent surgery remains challenging, and routine follow-up relies on imaging and imperfect serum biomarkers. OBJECTIVE: To assess whether longitudinal BRAF-mutant circulating tumour DNA (ctDNA) reflects disease status and whether time-updated ctDNA detection and concentration are associated with relapse hazard during post-resection surveillance....

Read the complete abstract on PubMed

Topics

Humans
Melanoma
Proto-Oncogene Proteins B-raf
Circulating Tumor DNA
Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Female

Skin Neoplasms

Prospective Studies

Middle Aged

Male

Mutation

Biomarkers, Tumor

Aged

Neoplasm Staging

Early Detection of Cancer

Adult

Longitudinal Studies

Source

Open in PubMed

Identifiers

PMID: 42532763
DOI: 10.1016/j.jdermsci.2026.07.004

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal BRAF ctDNA monitoring in melanoma reflects disease status and predicts relapse.PMID 42532763Read ↗

Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment.Semantic proximity Read ↗

Sensitivity and prognostic significance of circulating tumor DNA (ctDNA) in stage I to III malignant melanoma.Semantic proximity Read ↗

Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics.Semantic proximity Read ↗

Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma.Semantic proximity Read ↗

Dynamic ctDNA mutational complexity in melanoma patients receiving immunotherapySemantic proximity Read ↗

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.Semantic proximity Read ↗

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.Semantic proximity Read ↗

Pre-operative circulating tumour DNA in high-risk primary cutaneous melanoma: prospective feasibility in molecular pathology.Semantic proximity Read ↗

Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.Semantic proximity Read ↗

Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)Semantic proximity Read ↗

Serum‐based miRNAs in the prediction and detection of recurrence in melanoma patientsSemantic proximity Read ↗

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.